Voluntary nationwide recall: Methocarbamol (Eugia - March)
Apr. 2024Pharmacy Updates
Eugia US LLC is recalling one lot of Methocarbamol Injection, USP 1000 mg/10 mL (100 mg/mL). Methocarbamol is used for the relief of discomfort from acute, painful musculoskeletal conditions.
This drug is being recalled because white particles were found in one vial during a customer’s inspection. Using an injectable product that contains particulate matter may cause local irritation or swelling. It may also block blood vessels, leading to life-threatening blood clot events.
As of the date of Eugia’s recall announcement, March 28, 2024, there have been no reports of adverse events related to this recall. To see if your medication was recalled, contact your doctor or pharmacy where you received the medication or visit the FDA website below.
If you have an affected lot of Methocarbamol, you should stop using the item and return it to the place of purchase.
To learn more about this recall, you can take one or more of the steps below.
This drug is being recalled because white particles were found in one vial during a customer’s inspection. Using an injectable product that contains particulate matter may cause local irritation or swelling. It may also block blood vessels, leading to life-threatening blood clot events.
As of the date of Eugia’s recall announcement, March 28, 2024, there have been no reports of adverse events related to this recall. To see if your medication was recalled, contact your doctor or pharmacy where you received the medication or visit the FDA website below.
If you have an affected lot of Methocarbamol, you should stop using the item and return it to the place of purchase.
To learn more about this recall, you can take one or more of the steps below.
- Talk to your doctor or pharmacist.
- Call Eugia US LLC at 866-850-2876, option 2. TTY users should call 711. Help is available Monday through Friday from 8 a.m. to 5 p.m. EST.
- Visit the FDA website.
Recent Announcements
Voluntary nationwide recall: Ocaliva (Intercept – September)
Intercept Pharmaceuticals, Inc. is voluntarily withdrawing Ocaliva® (obeticholic acid) from the market. Ocaliva is used to treat a rare liver disease called primary biliary cholangitis (PBC).Oct. 2025Pharmacy Updates
HelpScript service helps patients enroll in manufacturer copay assistance programs
End-to-end provider support helps ensure a smooth submission processOct. 2025Important Notices
Important announcement – Telehealth submissions
As of October 1, 2025, UPMC Health Plan continues to accept the submission of telehealth claims. Providers may conduct telehealth visits for UPMC Health Plan members in all UPMC Insurance products. UPMC Insurance products include UPMC Advantage group and individual products, UPMC for Life Medicare Advantage plans, UPMC for Kids CHIP plans, UPMC Community HealthChoices, and UPMC for You Medical Assistance plans.Sep. 2025Important Notices